Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$27,000.00

A Pharmacogenomic- and Model Organism-Guided Approach to Identify Genetic Predictors of Morphine Ineffectiveness in Pediatric Oncology Patients

EF 2024-25

Résumé
Treatment for Canadian childhood cancer patients has improved dramatically over the years, to the point where overall 5-year survival rates now exceed 80%. However, many children undergoing chemotherapy experience painful drug-related side effects. Providing appropriate pain relief for these children is critical, yet many patients receive inadequate pain management. This is especially difficult in young children who cannot articulate their level of pain, limiting their ability to receive appropriate relief. Using pharmacogenomics (the study of how genetic differences contribute to individual drug responses), my project aims to identify genetic factors that could predict whether a child painful chemotherapy-related side effects may or may not be well-relieved by opioids. To this end, I will use statistical methods on a preexisting genetic and clinical database of childhood cancer patients to identify new genes that may have an impact on responses to opioids, as well as to explore the impacts of already-identified genes on opioid effectiveness. To functionally validate how identified genetic factors impact individual responses to opioids, I will take advantage of a pain management model developed using a nematode worm. Nematodes have a simple nervous system and simple behaviors, with genes that perform similar functions to those in humans. Using this model will allow me to validate the impacts of genetic factors on response to opioids in a controlled laboratory setting.Once identified and validated, genetic factors can then be used to develop predictive genetic tests. These tests can in turn help clinicians, patients, and their families, to make personalized treatment decisions, ultimately helping to alleviate pain from cancer treatment.
Programme
Master's Award: Canada Graduate Scholarships
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
529722
Name
Ernest-Hoar Graeme
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
A Pharmacogenomic- and Model Organism-Guided Approach to Identify Genetic Predictors of Morphine Ineffectiveness in Pediatric Oncology Patients
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adverse Drug Reactions; Bioinformatics; C. Elegans; Chemotherapeutics; Genomics; Opioids; Pain Management; Pediatrics; Pharmacogenomics; Pharmacology
Abstract
Treatment for Canadian childhood cancer patients has improved dramatically over the years, to the point where overall 5-year survival rates now exceed 80%. However, many children undergoing chemotherapy experience painful drug-related side effects. Providing appropriate pain relief for these children is critical, yet many patients receive inadequate pain management. This is especially difficult in young children who cannot articulate their level of pain, limiting their ability to receive appropriate relief. Using pharmacogenomics (the study of how genetic differences contribute to individual drug responses), my project aims to identify genetic factors that could predict whether a child painful chemotherapy-related side effects may or may not be well-relieved by opioids. To this end, I will use statistical methods on a preexisting genetic and clinical database of childhood cancer patients to identify new genes that may have an impact on responses to opioids, as well as to explore the impacts of already-identified genes on opioid effectiveness. To functionally validate how identified genetic factors impact individual responses to opioids, I will take advantage of a pain management model developed using a nematode worm. Nematodes have a simple nervous system and simple behaviors, with genes that perform similar functions to those in humans. Using this model will allow me to validate the impacts of genetic factors on response to opioids in a controlled laboratory setting.Once identified and validated, genetic factors can then be used to develop predictive genetic tests. These tests can in turn help clinicians, patients, and their families, to make personalized treatment decisions, ultimately helping to alleviate pain from cancer treatment.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ernest-Hoar, Graeme
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~